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Method
Highly efficient RNA-guided genome editing in human
cells via delivery of purified Cas9 ribonucleoproteins
Sojung Kim,1,2 Daesik Kim,1,2 Seung Woo Cho,1,2 Jungeun Kim,1,2 and Jin-Soo Kim1,2,3
1Department of Chemistry, Seoul National University, Seoul 151-747, South Korea; 2Center for Genome Engineering, Institute for
Basic Science, Seoul 151-747, South Korea
RNA-guided engineered nucleases (RGENs) derived from the prokaryotic adaptive immune system known as CRISPR
(clustered, regularly interspaced, short palindromic repeat)/Cas (CRISPR-associated) enable genome editing in human cell
lines, animals, and plants, but are limited by off-target effects and unwanted integration of DNA segments derived from
plasmids encoding Cas9 and guide RNA at both on-target and off-target sites in the genome. Here, we deliver purified
recombinant Cas9 protein and guide RNA into cultured human cells including hard-to-transfect fibroblasts and plu-
ripotent stem cells. RGEN ribonucleoproteins (RNPs) induce site-specific mutations at frequencies of up to 79%, while
reducing off-target mutations associated with plasmid transfection at off-target sites that differ by one or two nucleotides
from on-target sites. RGEN RNPs cleave chromosomal DNA almost immediately after delivery and are degraded rapidly
in cells, reducing off-target effects. Furthermore, RNP delivery is less stressful to human embryonic stem cells, producing
at least twofold more colonies than does plasmid transfection.
[Supplemental material is available for this article.]
The type II CRISPR (clustered, regularly interspaced, short palin-
dromic repeat)/Cas (CRISPR-associated) system is an adaptive im-
mune response in bacteria and archaea, which functions by rec-
ognizing and cleaving foreign DNA from phages and plasmids via
Cas9 protein and guide RNAs, whose sequences are partially derived
from the invaders (Horvath and Barrangou 2010; Wiedenheft et al.
2012). Recently, we and others exploited this system to develop
RNA-guided endonucleases or engineered nucleases (RGENs) that
enable targeted genome editing in cultured human cells (Cho et al.
2013a; Cong et al. 2013; Jinek et al. 2013; Mali et al. 2013b),
zebrafish embryos (Hwang et al. 2013), and bacteria (Jiang et al.
2013). Since then, RGENs have been successfully used to modify
genomes in various species including model organisms (Cho et al.
2013b; Dickinson et al. 2013; Friedland et al. 2013;Gratz et al. 2013;
Li et al. 2013a,c; Wang et al. 2013; Sung et al. 2014) and plants (Li
et al. 2013b;Nekrasov et al. 2013; Shan et al. 2013), rapidly catching
up with their precursors, namely, zinc finger nucleases (ZFNs)
(Bibikova et al. 2003; Porteus andBaltimore 2003) and transcription
activator-like effector nucleases (TALENs) (Miller et al. 2011).
Thus, RGENs are now a newmember in the growing family of
engineered nucleases (Kim and Kim 2014). These enzymes cleave
chromosomal DNA in cells, producing site-specific double-strand
breaks (DSBs), the repair of which via endogenous homologous
recombination (HR) or nonhomologous end joining (NHEJ) gives
rise to targeted mutagenesis and chromosomal rearrangements.
We have developed and improved all of these types of pro-
grammable nucleases over the last several years (Kim et al. 2009,
2010, 2011; Cho et al. 2013a; Kim et al. 2013a; Sung et al. 2013)
and reported that the specificity and activity of RGENs are at least
on par with those of their precursors. Unlike ZFNs and TALENs,
whose DNA-targeting specificities are altered by protein engi-
neering, new RGENs with desired specificities can be prepared
simply by replacing guide RNAs. Furthermore, use of in vitro
transcribed guide RNAs rather than plasmids that encode them
makes this system cloning-free (Cho et al. 2013a).
For efficient genome editing via RGENs, the successful delivery
of guide RNA andCas9 into cells is essential. In animal experiments,
in vitro transcribed Cas9-encoding mRNA or recombinant Cas9
protein can be directly injected into one-cell stage embryos using
glass needles to obtain genome-edited animals. To express Cas9
and guide RNA in cultured cells in vitro, typically, plasmids that
encode them are transfected via lipofection or electroporation.
Unfortunately, use of plasmids is often limited by random in-
tegration of all or part of the plasmid DNA into the host genome,
a process known as stable transfection. Plasmid DNA can also be
inserted at RGEN on-target and off-target sites (Gabriel et al. 2011).
Indeed, we found that at least one out of three large insertions and
six out of 26 (23%) small insertions at off-target sites, reported in
two recent papers (Cradick et al. 2013; Fu et al. 2013), were derived
from the Cas9- or sgRNA-encoding plasmid (Supplemental Table 1).
Unwanted insertions of plasmid DNA sequences at off-target sites
are difficult to detect and, therefore, more problematic than those
at on-target sites. These foreign sequences can cause host immune
responses (Hemmi et al. 2000; Wagner 2001), hampering the use of
gene-edited primary or stem cells in cell therapy. In addition, DNA
transfection is often stressful to cells. For example, plasmid DNA
introduced into cells triggers cyclic GMP-AMP synthase activation
(Sunet al. 2013). Furthermore, prolonged expressionof RGENs from
plasmid DNA, which can persist in cells for several days post-
transfection, can aggravate off-target effects (Gaj et al. 2012). In line
with these concerns, cells transfected with plasmids for biomedical
applications or animals and plants derived from DNA-transfected
cells are regarded as genetically modified by regulatory authorities
(Podevin et al. 2013; Pauwels et al. 2014), requiring a costly and
lengthy regulation procedure for approval in most developed
countries.
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In this study, we show that recombinant Cas9 protein com-
plexed with in vitro transcribed guide RNA can be delivered into
cultured human cells, including embryonic stem (ES) cells and fi-
broblasts, to sidestep many limitations associated with the use
of plasmids. RGEN ribonucleoproteins (RNPs) induce small in-
sertions and deletions (indels) at target sites almost immediately
after delivery into cells and are degraded rapidly, reducing off-
target effects.
Results
Targeted mutagenesis in human cells using RGEN RNPs
Recombinant Cas9 protein was purified from Escherichia coli
(Supplemental Fig. 1) and complexed with in vitro transcribed
single-chain guide RNA (sgRNA) composed of essential portions of
target-specific CRISPR RNA (crRNA) and target-independent trans-
activating crRNA (tracrRNA) or dualRNA that consists of crRNA
and tracrRNA. The resulting RNP complex was transfected into the
human leukemia K562 cell line via electroporation. At 48 h post-
transfection, RGEN-induced indel frequency was measured using
T7 endonuclease I (T7E1), which cleaves heteroduplexes formed
by the hybridization of mutant and wild-type sequences or two
different mutant sequences. The RGEN RNP designed to target the
CCR5 gene, which encodes a chemokine receptor that also acts as
an HIV co-receptor, was highly active, inducing mutations at fre-
quencies of up to 57% in a dose-dependentmanner, comparable to
that obtained with plasmids (Fig. 1A; Supplemental Fig. 2). Small
deletions or insertions, signature of error-prone DSB repair via
NHEJ, were observed at the target site (Fig. 1B), reminiscent of
those observed with ZFNs and TALENs (Kim et al. 2013b). We
found that up to sixfoldmolar excess of sgRNA over Cas9 protein is
required to maximize mutation frequencies (Supplemental Fig. 2).
To target several other loci in K562, we prepared new RGENs by
simply replacing sgRNA in the RNP complex. These RGENs de-
livered as RNPs were highly active, inducing mutations at fre-
quencies that ranged from 16% to 72% (Fig. 1C; Supplemental
Fig. 3). The averagemutation frequency obtainedwith RGENRNPs
at eight different sites in K562 cells was 44 6 7% under optimal
conditions. Note that T7E1 cannot cleave homoduplexes formed
by the hybridization of identical mutant sequences and, therefore,
often provides an underestimate of indel frequencies, especially
when nucleases are highly active, producing identical mutant se-
quences (Kim et al. 2014).
To rule out the possibility that RGEN RNPs cleave chromo-
somal DNA after cell lysis and that indels are produced by endog-
enous proteins associated with NHEJ in the cell lysate under cell-
free conditions rather than intracellularly (Budman and Chu
2005), we transfected Cas9 protein complexed with dualRNA
(rather than sgRNA) into K562 cells and isolated single cell-derived
clones via limiting dilution. DualRNAwas less potent than sgRNA.
Mutant clones were obtained at frequencies of 12% (Supplemental
Fig. 4). Furthermore, no mutations were detected using the T7E1
assay when cells were incubated with RGEN RNPs without elec-
troporation (data not shown). These results show that RGEN RNPs
entered cells and cleaved chromosomal DNA, triggering the for-
mation of indels at target sites.
Genome editing in human primary cells and embryonic stem
cells
We then investigated whether RGEN RNPs enable efficient ge-
nome editing in hard-to-transfect human primary cells such as BJ
fibroblasts and pluripotent stem cells such as H9 ES cells. In these
cells that are refractory to DNA transfection, RNP delivery via
electroporation was at least twofold more efficient than plasmid
Figure 1. Targeted mutagenesis in human K562 cells via direct delivery of RGEN RNPs. (A) CCR5-specific RGEN RNP-mediated mutations measured by
the T7E1 assay. (B) Mutant DNA sequences at the CCR5 locus. The 20-bp target sequence is underlined and shown in bold. The PAM sequence is shown in
red. (C ) RGEN RNP-mediated mutagenesis at several endogenous loci. A mixture of Cas9 protein (15 mg) and sgRNA (20 mg) was transfected into 23 105
K562 cells. PCR amplicons around RGEN target sites were subjected to the T7E1 assay. Representative data from at least three independent experiments
are shown.
Genome Research 1013
www.genome.org
RNA-guided genome editing via Cas9 RNP delivery
 Cold Spring Harbor Laboratory Press on June 12, 2014 - Published by genome.cshlp.orgDownloaded from 
transfection. Thus, the delivery of the CCR5-specific RGEN RNP
induced indels at frequencies of 19% and 23% in BJ fibroblasts and
H9 ES cells, respectively, whereas plasmid transfection gave rise to
indels at frequencies of 9% and 10%, respectively (Fig. 2A).We also
tested three other RGEN RNPs in H9 cells and found that the four
RGENs induced indels at a frequency of 20 6 3% on average
(Fig. 2B). Notably, RNP delivery was less toxic to ES cells, producing
at least twofold more colonies than did plasmid transfection (Fig.
2C). No apparent changes in the morphology of ES cell colonies
were observed after RGENRNP transfection (Fig. 2D). Furthermore,
all of the colonies expressed alkaline phosphatase, a marker for
pluripotency (Fig. 2D). These results suggest that use of RGENRNPs
rather than plasmids could facilitate isolation of genome-modified
clones of ES cells or induced pluripotent stem cells.
Oligonucleotide-directed genome editing via homology-
directed repair
Next,we investigatedwhether RGENRNPs canbe co-transfectedwith
homologous donor DNA to achieve genome editing via homology-
directed repair. We used single-stranded oligodeoxynucleotides
(ssODNs) (Chen et al. 2011) rather than gene-targeting vectors or
PCR amplicons as donor DNA to avoid the possibility that vector-
or amplicon-derived double-strand DNA segments could be
inserted randomly in the genome or specifically at RGEN on- or
off-target sites. Co-delivery of the AAVS1-specific RNP and an
ssODN containing a diagnostic XbaI site gave rise to targeted ge-
nome modification in K562 cells at a frequency of 15% measured
by XbaI digestion (Fig. 3). This method can be used to insert small
DNA sequences such as loxP or those that encode affinity tags or
antigens at pre-determined genomic sites.
Large chromosomal deletions induced by RGEN RNPs
We and others have shown that the repair of two concurrent DSBs
produced by ZFNs and TALENs gives rise to targeted chromosomal
rearrangements such as deletions, inversions, and translocations
(Brunet et al. 2009; Lee et al. 2010, 2012; Carlson et al. 2012; Kim
et al. 2013a). Likewise, transfection of plasmids that encode Cas9
and sgRNA into human cells can cause chromosomal deletions and
translocations in a targeted manner. We tested whether RGEN
RNPs can induce large chromosomal deletions in K562 cells. As
expected, use of two sgRNAswhose target sites are separated by 10-
to 100-kb pairs caused targeted deletions of corresponding chro-
mosomal segments (Fig. 4), demonstrating that RGEN RNP de-
livery enables multiplex genome engineering and targeted chro-
mosomal rearrangements.
Reducing off-target effects of RGENs via RNP delivery
RGENs can induce off-target mutations at sites that are highly
homologous to on-target sites (Cradick et al. 2013; Fu et al. 2013;
Hsu et al. 2013; Pattanayak et al. 2013; Cho et al. 2014). Off-target
DNA cleavages by RGENs can cause unwanted chromosomal
rearrangements such as translocations (Cho et al. 2014). We tested
whether RNP delivery could reduce off-target effects of RGENs. To
Figure 2. Genome editing in BJ fibroblasts and H9 hES cell lines via direct delivery of RGEN RNPs. (A) CCR5-specific RGEN-drivenmutations detected by
the T7E1 assay in H9 and BJ cells. (B) RGEN-drivenmutations in H9 ES cells detected by the T7E1 assay. A mixture of Cas9 protein (75 mg) and sgRNA (100
mg) was transfected into 1 3 106 H9 cells. (C ) Cytotoxicity of RGEN RNPs vs. RGEN plasmid in H9 ES cells. (**) P < 0.01, (*) P < 0.05. (D) No apparent
changes in the physiology of ES cells after RGEN RNP treatment. Untransfected, RNP-, and plasmid-transfected ES cell colonies were subjected to AP
staining.
Kim et al.
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this end, we chose three RGENs that were previously shown to
induce off-target mutations at high frequencies in human cells (Fu
et al. 2013; Cho et al. 2014) and compared RNP delivery with
plasmid transfection. The three RGENs delivered via RNPs were
highly active, inducing site-specific mutations at frequencies that
ranged from 76% to 79%, and discriminated on-target sites from
off-target sites more efficiently than did those delivered via plas-
mid transfection (Fig. 5). Thus, no mutations were detected using
the T7E1 assay at two off-target sites that differ by 2 nucleotides
(nt) from the on-target site, when the RGEN specific to the AAVS1-
S3 site was delivered via RNP electroporation. In contrast, the same
RGEN delivered via plasmids induced off-target mutations at these
sites at frequencies of 6% and 1%, respectively. Importantly, RNP
delivery did not sacrifice genome-editing activities at on-target
sites, while reducing off-target effects.
We then used deep sequencing to quantify off-target muta-
tions induced by RGENplasmids and RNPsmore accurately. Again,
the three RGEN RNPs discriminated on-target sites from off-target
sites muchmore efficiently than did plasmid-driven RGENs. Thus,
the RGEN RNP specific to the AAVS1-S3 site induced off-target
indels at frequencies of 0.15% and 0.06%. As a result, the ratio of
the indel frequency at the on-target site to that at the two off-target
sites was 114 and 279,whenRNPswere delivered,whereas the ratio
was 12 and 22, respectively, when plasmids were transfected,
demonstrating 9.5- (114/12) and 13-fold (279/22) differences, re-
spectively, between the two methods.
Figure 3. Homology-directed repair using ssODNs. The 86-mer ssODN
includes an XbaI restriction enzyme site, which is absent at the target site,
between two short homology arms. PCR amplicons were digested with
XbaI in an RFLP assay to detect sequences that resulted from homology-
directed repair.
Figure 4. Targeted chromosomal deletions via RGEN RNPs. (A) RGEN target sites in the region of the CCR5 locus. The distances between the CCR5 site
and each of the other sites are shown. Arrows indicate PCR primers. Red arrowheads indicate sgRNA target sites. (B) PCR products corresponding
to deletions in K562 cells treated with RGEN RNPs; 15mg of Cas9 protein premixedwith 20mg each of two sgRNAswas transfected into 23 105 K562 cells.
(C ) DNA sequences of deletion-specific PCR products. In cases in which a sequence was detected more than once, the number of occurrences is shown in
parentheses.
RNA-guided genome editing via Cas9 RNP delivery
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Kinetics of RGEN RNP-mediated genome editing
We performed a time-course T7E1 assay and Western blotting to
understand the molecular basis of the discrepancy between RNP
and plasmid delivery. The T7E1 assay showed that RGEN RNPs
cleaved chromosomal DNA almost immediately after delivery and
that the mutation frequency reached a plateau one day after
electroporation (Fig. 6). In contrast, it took three days to reach an
equivalent level of mutations when RGENs were expressed via
plasmid transfection. Western blotting analysis showed that Cas9
protein was rapidly degraded in cells when delivered directly: At
24 h post-transfection, Cas9 was barely detected. In contrast, Cas9
protein was expressed from plasmid for several days. Apparently,
continuous expression of Cas9 and sgRNA in cells gives rise to the
accumulation of off-target mutations. These results are in line with
those observed with the direct delivery of ZFNs, which reduces off-
target effects (Gaj et al. 2012). Unlike ZFN production, however,
preparation of new RGENs does not require time-consuming, fas-
tidious, and labor-intensive steps to de novo engineer, express, and
purify sequence-specific nucleases (Liu et al. 2014).
Discussion
RNA-guided genome editing with the repurposed type II CRISPR/
Cas system has been transforming almost every discipline in the
life sciences, biotechnology, and medicine (Kim and Kim 2014).
Compared with ZFNs and TALENs, RGENs are easy to make, af-
fordable, and scalable, lowering barriers to genome editing. How-
ever, these programmable nucleases are limited by off-target effects
and unwanted integration of plasmid vectors in the genome, un-
less mRNA or proteins are used. Furthermore, plasmid transfection
is often inefficient and stressful to cells. To sidestep these limita-
tions, we delivered RGEN RNPs, rather than plasmids, directly into
cells via electroporation and showed that RGEN RNPs enable effi-
cient genome editing even in human primary and ES cells that are
refractory to DNA transfection, while reducing off-target effects
and avoiding unwanted integration of plasmid DNA in the host
genome. In an accompanying paper published in this issue,
Ramakrishna et al. (2014) report that a cell-penetrating peptide
can be used to deliver both the Cas9 protein and sgRNA into hu-
man cells. In principle, Cas9 protein can be replaced with Cas9
mRNA. UnlikemRNA thatmust be translated in cells, Cas9 protein
works immediately after transfection into cells. Furthermore, it is
difficult to check the activity of Cas9 mRNA before transfection,
whereas the activity of Cas9 protein can be tested easily in vitro
before transfection. Cas9 protein can also be used for genotyping
of mutations induced by the same RGENs (Kim et al. 2014).
Recently, several groups independently reported that RGENs
can cause unwanted mutations at off-target sites that differ by up
to 5 nt from on-target sites, raising concerns about their specific-
ities (Cradick et al. 2013; Fu et al. 2013; Hsu et al. 2013; Pattanayak
et al. 2013). Off-target effects may result in chromosomal trans-
locations, inactivation of tumor suppressor or other essential
genes, and activation of oncogenes. We and others have proposed
several methods to reduce or avoid off-target effects of RGENs.
First, the concentration of sgRNA and Cas9 can be titrated to im-
prove the ratio of on-target to off-target mutation rates (Hsu et al.
2013). Unfortunately, titrating RGEN concentrations also reduces
on-targetmutation frequencies. Second, the use of guide RNAwith
Figure 5. Off-target mutations caused by RGEN RNPs vs. RGEN plasmids. RGEN RNPs or plasmids that encode Cas9 and sgRNA were electroporated
into K562 cells. Mutations were detected using the T7E1 assay (left) and deep sequencing (right). The PAM sequence is shown in blue. Mismatched bases
are shown in red.
Kim et al.
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two additional guanine bases at the 59 end (that do notmatchwith
target DNA sequences), termed 59-ggX20 sgRNA or crRNA, can
discriminate on-target sites from off-target sites that differ by 2 nt
efficiently without sacrificing on-target activities both in animals
(Cho et al. 2013b; Sung et al. 2014) and in cell lines (Cho et al.
2013a, 2014). Interestingly, truncated sgRNAs can also decrease
undesired off-targetmutations, improving the specificity of RGENs
(Fu et al. 2014). Third, paired Cas9 nickases (or RGENickases) that
generate two adjacent single-strand breaks on opposite DNA
strands, producing composite DSBs, double the specificity of RNA-
guided genome engineering (Mali et al. 2013a; Ran et al. 2013; Cho
et al. 2014), a strategy adopted from paired zinc finger nickases
(Kim et al. 2012). Fourth, as shown in this study, RGEN RNPs can
be used to reduce off-target effects. Last but not least, one should
choose unique target sites that do not have homologous sequences
elsewhere in the genome, a strategywe had used to avoid off-target
effects of TALENs (Kim et al. 2013a). A web-based computer pro-
gram that can be used for the identification of such sites is available
(Bae et al. 2014). It may even be possible to combine these ap-
proaches to avoid off-target effects completely. Thus, delivery of
RGENickase RNPs with two ggX20 sgRNAs to target a unique se-
quence in the genome may further reduce off-target effects that
persist even with the use of monomeric RGEN RNPs.
In conclusion, RGEN RNPs enable efficient and precise ge-
nome editing in diverse human cells including recalcitrant pri-
mary and pluripotent stem cells, while avoiding unwanted in-
tegration of plasmids and reducing off-target effects. We propose
that RGEN RNP delivery will broaden the utility of RNA-guided
genome engineering not only in basic research but also in bio-
medical applications and biotechnology by circumventing regu-
latory requirements associated with DNA transfection.
Methods
Cell culture
K562 (ATCC, CCL-243) cells were grown in RPMI-1640 with 10%
FBS and a penicillin/streptomycin mix. BJ (ATCC, CRL-2522) fi-
broblasts weremaintained in alpha-MEM supplemented with 10%
FBS, 0.1 mM nonessential amino acids, and a penicillin/strepto-
mycin mix. H9 human ES cells were maintained in DMEM/F12
(Gibco) supplemented with 20% knockout serum replacement
(Gibco), 0.1 mM 2-mercaptoethanol (Gibco), 1% nonessential
amino acids (Invitrogen), 8 ng/mL fibroblast growth factor-2
(Invitrogen), 50 U/mL penicillin, and 50 mg/mL streptomycin on
mitotically inactivated mouse stromal cells.
Recombinant Cas9 protein
Recombinant Cas9 protein was purchased from ToolGen, Inc. or
purified from E. coli. The Cas9 DNA sequence was subcloned into
pET28-b(+). Recombinant Cas9 protein containing a nuclear lo-
calization signal, theHA epitope, and theHis-tag at theN terminus
was expressed in BL21(DE3) strain, purified using Ni-NTA agarose
beads (Qiagen), and dialyzed against 20 mM HEPES pH 7.5,
150 mM KCl, 1 mM DTT, and 10% glycerol. The purified Cas9
protein was concentrated using Ultracel 100K cellulose column
(Millipore). The purity and concentration of Cas9 protein were
analyzed by SDS-PAGE.
Guide RNA
RNA was in vitro transcribed through run-off reactions by T7 RNA
polymerase using theMEGAshortscript T7 kit (Ambion) according
to the manufacturer’s manual. Templates for sgRNA or crRNAwere
Figure 6. Time-course analyses of RGEN-mediated genome editing via RNP delivery or plasmid transfection. (A, top) Mutation frequencies were
determined by the T7E1 assay. (Bottom) Western blot analysis of K562 cells transfected with the CCR5-specific RGEN via RNP or plasmid DNA delivery.
(B,C) Line graphs showing the results of the T7E1 (B) and Western blot analysis (C ). Note that only the relative abundance of Cas9 in each experiment
is shown.
RNA-guided genome editing via Cas9 RNP delivery
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generated by annealing and extension of two complementary oli-
gonuceotides (Supplemental Table 2). Transcribed RNAwas purified
by phenol:chloroform extraction, chloroform extraction, and eth-
anol precipitation. Purified RNA was quantified by spectrometry.
Transfection
To introduce DSBs inmammalian cells using an RNP complex, 23
105 cells were transfected with Cas9 protein (4.5–45 mg) premixed
with in vitro transcribed sgRNA (6–60 mg). Cas9 protein in storage
buffer (20 mM HEPES pH 7.5, 150 mM KCl, 1 mM DTT, and 10%
glycerol) was mixed with sgRNA dissolved in nuclease-free water
and incubated for 10min at room temperature. Nomore than 4 mL
of the RNP mixture was added to 20 mL of the Nucleofection so-
lution. For plasmid-mediated expression of RGENs, 2 3 105 cells
were co-transfected with 1 mg of Cas9-encoding plasmid and 1 mg
of sgRNA-expressing plasmid inK562 andBJ fibroblasts or 2.4mg of
Cas9-encoding plasmid and 1.6mg of sgRNA-expressing plasmid in
H9 hES cells. K562 cells were transfected with the Amaxa SF Cell
Line 4D-Nucleofector Kit using Program FF-120 (Lonza), and H9
and BJ cells were transfected with the Amaxa P3 Primary Cell 4D-
Nucleofector Kit using Program CB-150 and DT-130, respectively,
according to the manufacturer’s protocol. Cells were analyzed 2 d
after transfection, unless indicated otherwise.
Alkaline phosphatase (AP) staining
H9 human ES cells were fixed using 100% methanol for 10 min
and then washed twice with Dulbecco’s phosphate buffered saline
(DPBS). AP staining was performed using the AP staining kit
(Sigma) according to the manufacturer’s instructions. Briefly,
staining solution was prepared by mixing sodium nitrite solution,
FRV-Alkaline solution, and AS-BI alkaline solution. Cells were in-
cubated with the staining solution for 15 min and washed three
times with DPBS.
T7E1 assay
Genomic DNAwas isolated using a genome isolation kit (Promega)
according to the manufacturer’s instructions. PCR amplicons in-
cluding nuclease target sites were generated using the primers
listed in Supplemental Table 2. The T7E1 assay was performed as
previously described (Kim et al. 2009). Briefly, the PCR amplicons
were denatured by heating and annealed to form heteroduplex
DNA using a thermocycler and then digested with T7 endonucle-
ase 1 (New England Biolabs) for 20 min at 37°C and then analyzed
using agarose gel electrophoresis. For sequencing analysis, PCR
products corresponding to genomic modifications were purified and
cloned into the T-Blunt vector using the T-Blunt PCR Cloning Kit
(SolGent). Cloned products were sequenced using the M13 primer.
RFLP analysis for detection of ssODN-mediated homologous
recombination
A total of 23 105 K562 cells were co-transfected with 15mg of Cas9
protein mixed with 20 mg of in vitro transcribed sgRNA and 500
pmol of ssODN (Supplemental Table 2). After 48 h, genomic DNA
was isolated and subjected to PCR amplification with primers that
flank the target site (Supplemental Table 2). PCR amplicons were
digested with XbaI.
Targeted deep sequencing
The on-target and off-target regions were amplified using Phusion
polymerase (New England Biolabs) and used for library construc-
tion. Equal amounts of the PCR amplicons were subjected to
paired-end read sequencing using Illumina MiSeq at Bio Medical
Laboratories. Insertions or deletions located around the RGEN
cleavage site (3 bp upstream of the PAM) were considered to be the
mutations induced by RGENs.
Data access
The deep sequencing data are available at the NCBI Sequence Read
Archive (SRA) (http://www.ncbi.nlm.nih.gov/sra) under accession
number SRX473144.
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